Skip to main content
SpringerLink
Log in

Samarium 153Sm Lexidronam

  • Adis New Drug Profile
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

  • ▲ Samarium 153Sm lexidronam is a medium energy beta-emitting radioisotope chelated to the tetraphos-phate, ethylenediaminetetramethylenephosphonic acid (EDTMP). 153Sm has a physical half-life of 1.9 days.

  • ▲ Samarium 153Sm lexidronam concentrates in bone tissue and has a metastatic lesion: normal bone ratio of 4.

  • ▲ Clearance of nonskeletal radioactivity after administration of samarium 153Sm lexidronam is rapid, and is almost complete from the blood and urine within 1 and 6 hours, respectively.

  • ▲ Some degree of pain relief was achieved in 72% of patients with bone metastases after a single dose of samarium 153Sm lexidronam 1 mCi/kg (37 MBq/kg) compared with 44% of placebo recipients (p < 0.025). Relief was generally attained within 2 weeks and lasted for a median of 8 to 15 weeks.

  • ▲ After recurrence of pain, a second dose of samarium 153Sm lexidronam may produce further pain relief in some patients.

  • ▲ The dose-limiting toxicity of samarium 153Sm lexidronam is reversible myelosuppression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol 1991 Mar; 9(3): 509–24

    PubMed  CAS  Google Scholar 

  2. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997 Jan; 69: 1–18

    Article  PubMed  CAS  Google Scholar 

  3. Alberts AS, Brighton SW, Kempff P, et al. Samarium-153-EDTMP for palliation of ankylosing spondylitis, Paget’s disease and rheumatoid arthrids. J Nucl Med 1995 Aug; 36: 1417–20

    PubMed  CAS  Google Scholar 

  4. Quadramet (samarium-153 EDTMP). Clin Investigator News 1997 Apr: 15

  5. Silberstein EB. The treatment of painful osteoblastic metastases: what can we expect from nuclear oncology? J Nucl Med 1994 Dec; 35(12): 1994–5

    PubMed  CAS  Google Scholar 

  6. Coursey BM, Hoppes DD, Schima FJ, et al. The standardization of samarium-153. Int J Rad Appl lustrum A 1987; 38: 31–4

    Article  CAS  Google Scholar 

  7. DuPont Merck Pharmaceutical Company. Quadramet™ (samarium Sm 153 lexidronam injection) prescribing information. North Billerica, USA, Feb 1997

    Google Scholar 

  8. Singh A, Holmes RA, Farhangi M, et al. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J Nucl Med 1989; 30(11): 1814–8

    PubMed  CAS  Google Scholar 

  9. Collins C, Eary JF, Donaldson G, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 1993 Nov; 34: 1839–44

    PubMed  CAS  Google Scholar 

  10. Goeckeler WF, Edwards B, Volkert WA, et al. Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J Nucl Med 1987; 28(4): 495–504

    PubMed  Google Scholar 

  11. Winderen M, Kjønniksen I, Fodstad Ø. Pronounced therapeutic effect of samarium 153-ethylenediaminetetramethylene phosphonate in an orthotopic human osteosarcoma tibial tumor model. J Natl Cancer Inst 1995 Feb 1; 87: 221–2

    Article  PubMed  CAS  Google Scholar 

  12. Lattimer JC, Corwin Jr LA, Stapleton J, et al. Clinical and clinicopathologic response of canine bone tumor patients to treatment with samarium-153-EDTMP. J Nucl Med 1990; 31(8): 1316–25

    PubMed  CAS  Google Scholar 

  13. Farhanghi M, Holmes RA, Volkert WA, et al. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med 1992 Aug; 33: 1451–8

    PubMed  CAS  Google Scholar 

  14. Eary JF, Collins C, Stabin M, et al. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med 1993; 34(7): 1031–6

    PubMed  CAS  Google Scholar 

  15. Turner JH, Claringbold PG, Hetherington EL, et al. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. J Clin Oncol 1989 Dec; 7: 1926–31

    PubMed  CAS  Google Scholar 

  16. Fossella FV, Kasi L, Holoye P, et al. Phase I/II study of multidose samarium-153-EDTMP for bone metastases [abstract no. 210]. Ann Oncol 1992 Nov; 3 Suppl. 5: 54

    Google Scholar 

  17. Bayouth JE, Macey DJ, Kasi LP, et al. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med 1994; 35(1): 63–9

    PubMed  CAS  Google Scholar 

  18. Goeckeler WF, Stoneburner LK, Kasi LP, et al. Analysis of urine samples from metastatic bone cancer patients administered 153Sm-EDTMP. Nucl Med Biol 1993 Jul; 20: 657–61

    Article  PubMed  CAS  Google Scholar 

  19. Pusuwan P, Chaiwatanarat T, Chaudakshetrin P, et al. Pharmacokinetics of samarium-153-EDTMP in disseminated skeletal metastases. J Med Assoc Thai 1996 Sep; 79: 579–84

    PubMed  CAS  Google Scholar 

  20. Láznícek M, Láznícková A, Budsky F, et al. Comparison of biological characteristics of EDTMP complexes with 99Tc, 111In and 153Sm in rats. Appl Radiat Isot 1994 Sep; 45: 949–53

    Article  PubMed  Google Scholar 

  21. Turner JH, Mardndale AA, Sorby P, et al. Samarium-153 EDTMP therapy of disseminated skeletal metastasis. Eur J Nucl Med 1989; 15: 784–95

    Article  PubMed  CAS  Google Scholar 

  22. Sandeman TF, Budd RS, Mardn JJ. Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate. Clin Oncol R Coll Radiol 1992 May; 4: 160–4

    Article  PubMed  CAS  Google Scholar 

  23. Turner JH, Claringbold PG. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer 1991 Sep; 27: 1084–6

    Article  PubMed  CAS  Google Scholar 

  24. Houston SJ, Ramirez A, Lazarus CR, et al. Experience with samarium-153-EDTMP for the treatment of patients with painful bone metastases [abstract no. P182]. Br J Cancer 1995 Apr; 71 Suppl. 24: 69

    Google Scholar 

  25. Deng H, Luo S, Tan T, et al. 153Sm-EDTMP for moderate and severe bone cancer pain [in Chinese]. J West China Univ Med Sci 1995 Dec; 26: 391–4

    CAS  Google Scholar 

  26. Jiang C, Zhu B, Zhang Y. The value of Sm-153-EDTMP for treatment of metastatic bone pain and improving quality of life [in Chinese]. Chin J Oncol 1994; 16(2): 118–21

    CAS  Google Scholar 

  27. Zou B-M, Hu G-Y, Yu M-Q. Treatment of bone metastases with 153-Sm-EDTMP [in Chinese]. Chin J Clin Oncol 1995; 22(10): 733–5

    Google Scholar 

  28. Sartor O, Quick D, Reid R, et al. A double blind placebo controlled study of 153samarium-EDTMP for palliation of bone pain in patients with hormone-refractory prostate cancer [abstract no. 1252]. J Urol 1997 Apr; 157 Suppl.: 321

    Google Scholar 

  29. Serafini A, Quick D, Houston S, et al. Sm-153-EDTMP as palliadve agent for patients with bone metastases [abstract no. 117]. J Nucl Med 1996 May; 37 Suppl.: 32P

    Google Scholar 

  30. Resche I, Chatal J-F, Pecking A, et al. A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 1997; 33(10): 1583–91

    Article  PubMed  CAS  Google Scholar 

  31. Quadramet (samarium-153 EDTMP). Clin Investigator News 1997 Apr: 25

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Harriet M. Lamb & Diana Faulds

Authors
  1. Harriet M. Lamb
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Diana Faulds
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Harriet M. Lamb.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lamb, H.M., Faulds, D. Samarium 153Sm Lexidronam. Drugs & Aging 11, 413–418 (1997). https://doi.org/10.2165/00002512-199711050-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199711050-00007

Keywords

Search

Navigation